AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01853124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
Study NCT01853124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidofil
Description: All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
Study NCT01467739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu ® aScope®
Study NCT01467739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a conventional reusable fiberscope
Study NCT06695182 — intervention group
Intervention type: BEHAVIORAL
Intervention: physical activity
Study NCT00765362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encore Mobile-Bearing Knee
Description: Used for primary total knee replacement
Study NCT03254693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 1-step self-etch approach (SE)
Description: Application mode - Do not use etchan. According to the manufacturer's instructions.
Study NCT03254693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: selective enamel etching (SEE)
Description: Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
Study NCT03254693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-step self-etch for double time (SE2X)
Description: Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
Study NCT03254693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-step self-etch additional layer (SE1+)
Description: Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
Study NCT03046303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
Study NCT01639274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COPD prevalence
Description: Determine prevalence of COPD
Study NCT02033993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Study NCT02033993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT00583180 — intervention group
Intervention type: DRUG
Intervention: Capsaicin
Description: instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
Study NCT03271255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
Study NCT03271255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
Study NCT03664817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social capital intervention
Description: The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
Study NCT03664817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group-based health promotion intervention
Description: The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan).
Study NCT03312673 — intervention group
Intervention type: OTHER
Intervention: Interview and tests of drawing.
Description: The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
Study NCT06246825 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
Study NCT02109003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure easy® device
Description: Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
Study NCT02109003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual control of Pcuff followed by continuous control.
Description: Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
Study NCT00671541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merogel Nasal Stent and Nasopore Stent
Description: Merogel Nasal Stent and Nasopore Stent
Study NCT06375798 — intervention group
Intervention type: PROCEDURE
Intervention: radiotherapy
Description: If the postoperative paraffin pathology of patients in the IORT group indicated positive axillary lymph nodes, the radiologist should determine whether to irradiate the whole milk and lymph nodes in the drainage area.If the postoperative pathology of patients in the WBI group indicated the need for chemotherapy, radiotherapy was initiated within 6 weeks after the end of chemotherapy, allowing both endocrine therapy and radiotherapy to be performed simultaneously. Clinical standard treatment plan (chemotherapy, endocrine therapy, etc.) was developed based on postoperative pathological and immunohistochemical reports.
Study NCT03911570 — intervention group
Intervention type: DRUG
Intervention: Glucosamine Sulfate
Description: Therapy with the prescription formulation of crystalline glucosamine sulfate
Study NCT00803244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR
Description: 300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
Study NCT00803244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
Study NCT02512016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study Procedures
Description: * Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings.
Study NCT04652687 — intervention group
Intervention type: OTHER
Intervention: VIA Disc NP (HCT/P)
Description: VIA Disc NP - Allograft tissue injection
Study NCT02026271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12
Study NCT02026271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veledimex
Description: * 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD
Study NCT00477529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-008
Description: nab-docetaxel
Study NCT02617758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
Study NCT02617758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
Study NCT00671541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merogel Nasal Stent and Nasopore Stent
Description: Merogel Nasal Stent and Nasopore Stent
Study NCT00671541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasopore Stent and either Gentamycin or Bacitracin
Description: Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
Study NCT00623415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupirtine
Description: 300 mg daily (divided in two doses)
Study NCT00623415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT03136250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A (Control Group - Static Stretching + Standard Treatment)
Description: o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
Study NCT03136250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B (Autogenic Inhibition - PIR + Standard treatment)
Description: o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
Study NCT03136250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C (Reciprocal Inhibition - RI + Standard treatment)
Description: o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
Study NCT00283738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioSTAR Septal Repair Implant System
Description: PFO Closure
Study NCT00283738 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Procedure
Description: Catheterization
Study NCT04192812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREOPERATİVE GnRHa THERAPY (LEUPROLIDE ACETATE) BEFORE SURGERY FOR UTERİN FIBROIDS
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Study NCT04192812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NO GnRHa
Description: THE EFFICACY OF PREOPERATIVE USAGE OF GnRHa IN PATIENTS UNDERGOING TOTAL LAPAROSCOPIC HYSTERECTOMY DUE TO UTERIN FIBROIDS
Study NCT02763540 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung cryobiopsy
Description: Transbronchial cryobiopsy
Study NCT01587729 — intervention group
Intervention type: DRUG
Intervention: Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
Description: TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
Study NCT03026569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL/d)
Description: The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
Study NCT02602457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-intensity continuous exercise training
Description: Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
Study NCT02602457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training
Description: Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
Study NCT00178256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
Study NCT03152864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Package
Description: Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
Study NCT03653715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clerio Vision LIRIC-modified Bifocal Contact Lens
Description: Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
Study NCT03653715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens
Description: Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
Study NCT03653715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson & Johnson 1-Day Acuvue Moist Contact Lens
Description: Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
Study NCT03653715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clerio Vision Single Vision Contact Lens
Description: Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
Study NCT02028689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg
Study NCT02028689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Study NCT02028689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ha44
Description: Abametapir Lotion 0.74%
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ha44 Placebo
Description: Ha44 Vehicle Gel without Abametapir
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ha44 Placebo
Description: Ha44 Vehicle Gel without Abametapir
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin Placebo
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Moxifloxacin Placebo
Study NCT01518699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg
Study NCT01301911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipatinib
Description: Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
Study NCT01184989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dabigatran etexilate
Description: once daily approved dose by EMEA and Health Canada
Study NCT01277224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movi2 Program
Description: In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
Study NCT01201369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Stent Cypher
Description: The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
Study NCT01201369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stent Xience
Description: The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
Study NCT02101411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PRU(Platelet reactivity unit)
Description: measure by VeryfyNow.
Study NCT01426048 — intervention group
Intervention type: OTHER
Intervention: Gynaecological examination and a supine stress test, questionnaires
Description: Gynaecological examination and a supine stress test, questionnaires
Study NCT03212547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Intervention
Description: Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet.
Study NCT03102736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo saline
Study NCT03102736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg ketamine
Study NCT03102736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/kg ketamine
Study NCT03102736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Description: 0.5 mcg/kg nitroprusside
Study NCT01618981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pace make active/inactive cross over
Study NCT03486535 — intervention group
Intervention type: DRUG
Intervention: Infraclavicular Brachial Plexus Blocks
Description: All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
Study NCT03486535 — intervention group
Intervention type: DRUG
Intervention: Infraclavicular Brachial Plexus Blocks
Description: All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.